Findings from the Longitudinal CINRG Becker Natural History Study
BACKGROUND: Becker muscular dystrophy is an X-linked, genetic disorder causing progressive degeneration of skeletal and cardiac muscle, with a widely variable phenotype.
OBJECTIVE: A 3-year, longitudinal, prospective dataset contributed by patients with confirmed Becker muscular dystrophy was analyzed to characterize the natural history of this disorder. A better understanding of the natural history is crucial to rigorous therapeutic trials.
METHODS: A cohort of 83 patients with Becker muscular dystrophy (5-75 years at baseline) were followed for up to 3 years with annual assessments. Muscle and pulmonary function outcomes were analyzed herein. Age-stratified statistical analysis and modeling were conducted to analyze cross-sectional data, time-to-event data, and longitudinal data to characterize these clinical outcomes.
RESULTS: Deletion mutations of dystrophin exons 45-47 or 45-48 were most common. Subgroup analysis showed greater pairwise association between motor outcomes at baseline than association between these outcomes and age. Stronger correlations between outcomes for adults than for those under 18 years were also observed. Using cross-sectional binning analysis, a ceiling effect was seen for North Star Ambulatory Assessment but not for other functional outcomes. Longitudinal analysis showed a decline in percentage predicted forced vital capacity over the life span. There was relative stability or improved median function for motor functional outcomes through childhood and adolescence and decreasing function with age thereafter.
CONCLUSIONS: There is variable progression of outcomes resulting in significant heterogeneity of the clinical phenotype of Becker muscular dystrophy. Disease progression is largely manifest in adulthood. There are implications for clinical trial design revealed by this longitudinal analysis of a Becker natural history dataset.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Journal of neuromuscular diseases - 11(2024), 1 vom: 24., Seite 201-212 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Clemens, Paula R [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Dystrophin |
|---|
| Anmerkungen: |
Date Completed 09.01.2024 Date Revised 10.02.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.3233/JND-230178 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36472210X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36472210X | ||
| 003 | DE-627 | ||
| 005 | 20240210232918.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3233/JND-230178 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1287.xml |
| 035 | |a (DE-627)NLM36472210X | ||
| 035 | |a (NLM)37980682 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Clemens, Paula R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Findings from the Longitudinal CINRG Becker Natural History Study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.01.2024 | ||
| 500 | |a Date Revised 10.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Becker muscular dystrophy is an X-linked, genetic disorder causing progressive degeneration of skeletal and cardiac muscle, with a widely variable phenotype | ||
| 520 | |a OBJECTIVE: A 3-year, longitudinal, prospective dataset contributed by patients with confirmed Becker muscular dystrophy was analyzed to characterize the natural history of this disorder. A better understanding of the natural history is crucial to rigorous therapeutic trials | ||
| 520 | |a METHODS: A cohort of 83 patients with Becker muscular dystrophy (5-75 years at baseline) were followed for up to 3 years with annual assessments. Muscle and pulmonary function outcomes were analyzed herein. Age-stratified statistical analysis and modeling were conducted to analyze cross-sectional data, time-to-event data, and longitudinal data to characterize these clinical outcomes | ||
| 520 | |a RESULTS: Deletion mutations of dystrophin exons 45-47 or 45-48 were most common. Subgroup analysis showed greater pairwise association between motor outcomes at baseline than association between these outcomes and age. Stronger correlations between outcomes for adults than for those under 18 years were also observed. Using cross-sectional binning analysis, a ceiling effect was seen for North Star Ambulatory Assessment but not for other functional outcomes. Longitudinal analysis showed a decline in percentage predicted forced vital capacity over the life span. There was relative stability or improved median function for motor functional outcomes through childhood and adolescence and decreasing function with age thereafter | ||
| 520 | |a CONCLUSIONS: There is variable progression of outcomes resulting in significant heterogeneity of the clinical phenotype of Becker muscular dystrophy. Disease progression is largely manifest in adulthood. There are implications for clinical trial design revealed by this longitudinal analysis of a Becker natural history dataset | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Muscular dystrophies | |
| 650 | 4 | |a dystrophin | |
| 650 | 4 | |a muscle | |
| 650 | 4 | |a natural history | |
| 650 | 4 | |a skeletal | |
| 700 | 1 | |a Gordish-Dressman, Heather |e verfasserin |4 aut | |
| 700 | 1 | |a Niizawa, Gabriela |e verfasserin |4 aut | |
| 700 | 1 | |a Gorni, Ksenija |e verfasserin |4 aut | |
| 700 | 1 | |a Guglieri, Michela |e verfasserin |4 aut | |
| 700 | 1 | |a Connolly, Anne M |e verfasserin |4 aut | |
| 700 | 1 | |a Wicklund, Matthew |e verfasserin |4 aut | |
| 700 | 1 | |a Bertorini, Tulio |e verfasserin |4 aut | |
| 700 | 1 | |a Mah, Jean |e verfasserin |4 aut | |
| 700 | 1 | |a Thangarajh, Mathula |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Edward C |e verfasserin |4 aut | |
| 700 | 1 | |a Kuntz, Nancy L |e verfasserin |4 aut | |
| 700 | 1 | |a McDonald, Craig M |e verfasserin |4 aut | |
| 700 | 1 | |a Henricson, Erik |e verfasserin |4 aut | |
| 700 | 1 | |a Upadhyayula, S |e verfasserin |4 aut | |
| 700 | 1 | |a Byrne, Barry |e verfasserin |4 aut | |
| 700 | 1 | |a Manousakis, Georgios |e verfasserin |4 aut | |
| 700 | 1 | |a Harper, Amy |e verfasserin |4 aut | |
| 700 | 1 | |a Iannaccone, Susan |e verfasserin |4 aut | |
| 700 | 1 | |a Dang, Utkarsh J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of neuromuscular diseases |d 2014 |g 11(2024), 1 vom: 24., Seite 201-212 |w (DE-627)NLM246466057 |x 2214-3599 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2024 |g number:1 |g day:24 |g pages:201-212 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3233/JND-230178 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2024 |e 1 |b 24 |h 201-212 | ||